MyFinsight
Home
Blog
About
Proceeds from exercise of
share options
$16,485K
(164.99%↑ Y/Y)
Increase in accrued
expenses
$27,001K
(18.49%↑ Y/Y)
Share-based compensation
expense
$9,404K
(-51.83%↓ Y/Y)
(increase) decrease in
prepayments and other...
-$2,097K
(-474.52%↓ Y/Y)
Depreciation
$1,026K
(-37.21%↓ Y/Y)
Unrealized foreign
exchange gains, net
-$808K
(-233.11%↓ Y/Y)
Non-cash lease expense
$610K
(-45.24%↓ Y/Y)
Other
-$546K
(47.95%↑ Y/Y)
Net cash provided by
financing activities
$16,485K
(164.99%↑ Y/Y)
Net cash provided by
operating activities
$15,928K
(-39.66%↓ Y/Y)
Canceled cashflow
$25,564K
Total revenue
$115,927K
(-39.57%↓ Y/Y)
Increase in cash and cash
equivalents
$31,627K
(165.59%↑ Y/Y)
Canceled cashflow
$786K
Increase in accounts
receivable
$14,621K
(337.62%↑ Y/Y)
Increase (decrease) in
accounts payable
-$4,803K
(-33.90%↓ Y/Y)
Unrealized gains on
marketable securities
$3,071K
(-69.78%↓ Y/Y)
Decrease in operating
lease liabilities
-$1,360K
(-157.58%↓ Y/Y)
Net income (loss)
-$808K
(84.69%↑ Y/Y)
Decrease in other
operating assets
$755K
(121.41%↑ Y/Y)
Decrease in deferred
revenue
-$146K
(-50.52%↓ Y/Y)
Canceled cashflow
$115,927K
Net cash provided by
(used in) investing...
-$786K
(96.21%↑ Y/Y)
R&d
expenses-External RD
$48,831K
(157.04%↑ Y/Y)
Sg&a expenses-Other
Selling General And...
$23,347K
(154.40%↑ Y/Y)
Other segment
(expense) income, net
$15,305K
(186.32%↑ Y/Y)
R&d
expenses-Salaries And Other...
$14,258K
(159.53%↑ Y/Y)
Sg&a
expenses-Salaries And Other...
$13,906K
(155.52%↑ Y/Y)
Cost of revenue from
sale of therapies
$1,088K
(158.15%↑ Y/Y)
Purchase of property and
equipment
$786K
(10.39%↑ Y/Y)
PRAMEPrograms
$20,091K
(152.89%↑ Y/Y)
Other Clinical And Pre
Clinical Costs
$16,352K
(161.74%↑ Y/Y)
Tebentafusp Programs
$11,863K
(164.45%↑ Y/Y)
Infectious Disease
Programs
$525K
(119.23%↑ Y/Y)
Back
Back
Cash Flow
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)
source: myfinsight.com